View expert index
View all diseases
View all trials
View all medicines
EMMA Vienna 2017
View upcoming conferences
View previous conferences
Acute Myeloid Leukemia
Why should elderly AML patients take part in clinical trials?
Mhairi Copland, PhD, MB, ChB, MRCP, FRCPath, from the University of Glasgow, Glasgow, UK, discusses why elderly acute myeloid leukemia…
Where will leukemia research go next?
John Gribben, MD, DSc, FRCPath, FMed Sci, from the Barts Cancer Institute, London, UK, discusses the future of leukemia research…
Why do charities need to keep funding research into leukemia and blood cancer in general?
John Gribben, MD, DSc, FRCPath, FMed Sci, from the Barts Cancer Institute, London, UK, explains why continued funding for research…
Improving the outcomes of transplantation with bispecific antibodies
Hermann Einsele, MD, from the University Hospital Würzburg, Würzburg, Germany, discusses the use of bispecific antibodies before and after allogeneic…
Improving T-cell therapy with antigen specific T-cells
Catherine Bollard, MBChB, MD, FRACP, FRCPA, from the Children’s Research Institute, Washington, DC, speaks about improving T-cell therapy at the…
Prospect of new therapies for AML
Mhairi Copland, PhD, MB, ChB, MRCP, FRCPath from the University of Glasgow, Glasgow, UK, gives an overview of the session…
How the treatment of AML will change
Mary Frances McMullin
Mary Frances McMullin, MD of Belfast City Hospital, Belfast, UK discusses targeted therapy and immunotherapy for acute myeloid leukemia (AML)…
Managing transplant ineligible AML patients
Mhairi Copland, PhD, MB, ChB, MRCP, FRCPath from the University of Glasgow, Glasgow, UK, discusses the management of transplant ineligible…
New targets to treat acute myeloid leukemia (AML) with FLT3 mutations
Keith Pratz, MD, from Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses new treatment targets for acute myeloid…
Treating acute myeloid leukemia with VALOR – vosaroxin in combination with cytarabine
Farhad Ravandi, MD from the University of Texas MD Anderson Cancer Center, Houston, TX, explains results from the VALOR trial…
Sign up for the latest news and videos
Is CLL curable today?
How far are we from a cure for CLL?
Mechanism of action of venetoclax (ABT-199) and its side effects
Myeloma 2016: Panel discussion on novel treatments
Highlights from the International Workshop of the German CLL Study Group